Antibody-enabled small-molecule drug discovery

Nature Reviews Drug Discovery

Volumn 11, Issue 7, 2012, Pages 519-525

  Lawson, Alastair D G ^a  

^a UCB Celltech   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAMELID DERIVED SINGLE DOMAIN VARIABLE HEAVY CHAIN FRAGMENT ANTIBODY; CHAPERONE; IMMUNOGLOBULIN F(AB) FRAGMENT; LOW DENSITY LIPOPROTEIN RECEPTOR; NEW DRUG; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL MOLECULE DRUG; UNCLASSIFIED DRUG;

ALLOSTERISM; ANTIBODY COMBINING SITE; CRYSTALLOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RECEPTOR BLOCKING; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CRYSTALLOGRAPHY, X-RAY; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MUROMONAB-CD3; REPRODUCIBILITY OF RESULTS;

EID: 84863209627     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3756     Document Type: Review

References (65)

1. Ramani, A. K., Bunescu, R. C., Mooney, R. J. & Marcotte, E. M. Consolidating the set of known human protein-protein interactions in preparation for large-scale mapping of the human interactome. Genome Biol. 6, R40 (2005).
2. Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007). (Pubitemid 350273630)
3. Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Rev. Drug Discov. 3, 301-317 (2004). (Pubitemid 38499758)
4. Dickens, M. P., Fitzgerald, R. & Fischer, P. M. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin. Cancer Biol. 20, 10-18 (2010).
5. Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011).
6. Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996). (Pubitemid 26403929)
7. Hajduk, P. J. & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nature Rev. Drug Discov. 6, 211-219 (2007). (Pubitemid 46344625)
8. Jhoti, H. Fragment-based drug discovery using rational design. Ernst Schering Found. Symp. Proc. 3, 169-185 (2007).
9. Murray, C. W. & Rees, D. C. The rise of fragment-based drug discovery. Nature Chem. 1, 187-192 (2009).
10. Valkov, E., Sharpe, T., Marsh, M., Grieve, S. & Hyvönen, M. Targeting protein-protein interactions and fragment-based drug discovery. Top. Curr. Chem. 317, 145-179 (2012).
11. Sun, C., Petros, A. M. & Hajduk, P. J. Fragment-based lead discovery: challenges and opportunities. J. Comput. Aided Mol. Des. 25, 607-610 (2011).
12. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genet. 34, 154-156 (2003). (Pubitemid 36666925)
13. Seidah, N. G. & Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nature Rev. Drug Discov. 11, 367-383 (2012).
14. Crunkhorn, S. PCSK9 antibody reduces LDL cholesterol. Nature Rev. Drug Discov. 11, 11 (2012).
15. Paalanen, M. M. I. et al. The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon. Eur. J. Pharm. Sci. 42, 332-339 (2011).
16. Haque, A., Anderson, J. N., Salmeen, A., Barford, D. & Tonks, N. K. Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell 147, 185-198 (2011).
17. Visintin, M., Melchionna, T., Cannistraci, I. & Cattaneo, A. In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an 'undruggable' class of disease targets. J. Biotechnol. 135, 1-15 (2008).
18. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001). (Pubitemid 32494397)
19. DeLano, W. L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol. 12, 14-20 (2002).
20. Ganesan, R. et al. Unraveling the allosteric mechanism of serine protease inhibition by an antibody. Structure 17, 1614-1624 (2009).
21. Barlow, J. N., Conrath, K. & Steyaert, J. Substrate-dependent modulation of enzyme activity by allosteric effector antibodies. Biochim. Biophys. Acta 1794, 1259-1268 (2009).
22. Dong, J. et al. A single domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic α-exosite binding region. J. Mol. Biol. 397, 1106-1118 (2010).
23. Air, G. M., Webster, R. G., Colman, P. M. & Laver, W. G. Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. Virology 160, 346-354 (1987).
24. Ostermeier, C., Harrenga, A., Ermler, U. & Michel, H. Structure at 2.7Å resolution of the Paracoccus denitrificans two-subunit cytochrome c oxidase complexed with an antibody Fv fragment. Proc. Natl Acad. Sci. USA 94, 10547-10553 (1997).
25. Kortt, A. A. et al. Recombinant anti-sialidase single chain variable fragment antibody. Characterisation, formation of dimer and higher-molecular- mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur. J. Biochem. 221, 151-157 (1994). (Pubitemid 24120557)
26. Loris, R. et al. Crystal structure of the intrinsically flexible addiction antidote MazE. J. Biol. Chem. 278, 28252-28257 (2003). (Pubitemid 36900026)
27. Tereshko, V. et al. Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold. Protein Sci. 17, 1175-1187 (2008). (Pubitemid 351930915)
28. Wu, M. et al. Structures of a key interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodies. J. Struct. Biol. 174, 124-136 (2011).
29. Korotkov, K. V., Pardon, E., Steyaert, J. & Hoi, W. G. J. Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. Structure 17, 255-265 (2009).
30. Zhou, Y., Morais-Cabral, J. H., Kaufman, A. & MacKinnon, R. Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0Å resolution. Nature 414, 43-48 (2001). (Pubitemid 33041616)
31. Lam, A. Y., Pardon, E., Korotkov, K. V., Hol, W. G. & Steyaert, J. Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. J. Struct. Biol. 166, 8-15 (2009).
32. Iwata, S., Ostermeier, C., Ludwig, B. & Michel, H. Structure at 2.8Å resolution of cytochrome c oxidase from Paracoccus denitrificans. Nature 376, 660-669 (1995).
33. Streltsov, V. A., Varghese, J. N., Masters, C. L. & Nuttall, S. D. Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease. J. Neurosci. 31, 1419-1426 (2011).
34. Pai, J. C. et al. Conversion of scFv peptide-binding specificity for crystal chaperone development. Protein Eng. Des. Sel. 24, 419-428 (2011).
35. Prongay, A. J. et al. Preparation and crystallization of a human immunodeficiency virus p24-Fab complex. Proc. Natl Acad. Sci. USA 87, 9980-9984 (1990). (Pubitemid 120016568)
36. Hino, T. et al. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482, 237-240 (2012).
37. Rasmussen, S. G. F. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175-181 (2011).
38. Rizk, S. S. et al. Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins. Nature Struct. Mol. Biol. 18, 437-444 (2011).
39. Domanska, K. et al. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic β2-microglobulin variant. Proc. Natl Acad. Sci. USA 108, 1314-1319 (2011).
40. Saragovi, H. U. et al. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science 253, 792-795 (1991). (Pubitemid 21917219)
41. Sadowsky, J. D. et al. Turning a protein kinase on or off from a single allosteric site via disulphide trapping. Proc. Natl Acad. Sci. USA 108, 6056-6061 (2011).
42. Lobato, M. N. & Rabbitts, T. H. Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol. Med. 9, 390-396 (2003). (Pubitemid 37169053)
43. Oyen, D., Srinivasan, V., Steyaert, J. & Barlow, J. N. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. J. Mol. Biol. 407, 138-148 (2011).
44. Gao, J., Sidhu, S. S. & Wells, J. A. Two-state selection of conformation-specific antibodies. Proc. Natl Acad. Sci. USA 106, 3071-3076 (2009).
45. De Genst, E. J. et al. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J. Mol. Biol. 402, 326-343 (2010).
46. Lafaye, P., Achour, I., England, P., Duyckaerts, C. & Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 46, 695-704 (2009).
47. Habicht, G. et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc. Natl Acad. Sci. USA 104, 19232-19237 (2007).
48. Dumoulin, M. et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424, 783-788 (2003). (Pubitemid 37021708)
49. Abskharon, R. N. et al. Crystallization and preliminary X-ray diffraction analysis of a specific VHH domain against mouse prion protein. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Crystallogr. 66, 1644-1646 (2010).
50. Mossessova, E., Corpina, R. A. & Goldberg, J. Crystal structure of ARF1*Sec7 complexed with brefeldin A and its implications for the guanine nucleotide exchange mechanism. Mol. Cell 12, 1403-1411 (2003). (Pubitemid 38037010)
51. Viaud, J. et al. Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein-protein complexes. Proc. Natl Acad. Sci. USA 104, 10370-10375 (2007). (Pubitemid 47185672)
52. Monod, J., Changeux, J. P. & Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol. 6, 306-329 (1963).
53. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discov. 1, 198-210 (2002). (Pubitemid 37361423)
54. Gunasekaran, K., Ma, B. & Nussinov, R. Is allostery an intrinsic property of all dynamic proteins? Proteins 57, 433-443 (2004). (Pubitemid 39390799)
55. Horn, J. R. & Shoichet, B. K. Allosteric inhibition through core disruption. J. Mol. Biol. 336, 1283-1291 (2004). (Pubitemid 38229713)
56. Gonzαlez-Ruiz, D. & Gohlke, H. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem. 13, 2607-2625 (2006). (Pubitemid 44364140)
57. Ganesan, R., Eigenbrot, C. & Kirchhofer, D. Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochem. J. 430, 179-189 (2010).
58. Murray, C. W. & Blundell, T. L. Structural biology in fragment-based drug design. Curr. Opin. Struct. Biol. 20, 497-507 (2010).
59. Giannetti, A. M. From experimental design to validated hits: a comprehensive walk-through of fragment lead identification using surface plasmon resonance. Methods Enzymol. 493, 169-218 (2011).
60. Perspicace, S. et al. Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen. 14, 337-349 (2009).
61. Hδmδlδinen, M. D. et al. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. J. Biomol. Screen. 13, 202-209 (2008). (Pubitemid 351322871)
62. Hajduk, P. J., Meadows, R. P. & Fesik, S. W. NMR-based screening in drug discovery. Q. Rev. Biophys. 32, 211-240 (1999). (Pubitemid 30598968)
63. Edink, E. et al. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. J. Am. Chem. Soc. 133, 5363-5371 (2011).
64. Koldobskaya, Y. et al. A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination. Nature Struct. Mol. Biol. 18, 100-106 (2011).
65. Tickle, S. et al. High-throughput screening for high affinity antibodies. J. Lab. Autom. 14, 303-307 (2009).